CRISPR Therapeutics AG CRSP Cash Flow Statement (2015-2026)

NASDAQ CRSP
$56.00 +1.91 (+3.53%)
At close: Sep 29, 2026 · 4:00 PM EDT
Reported Financials

CRISPR Therapeutics AG Quarterly Cash Flow Statement

Periods 44 quarters
Latest Jun 2026

CRISPR Therapeutics AG reported cash from operations of -$83.50M and free cash flow of -$84.15M for the quarter ended Jun 2026, up 26.7% year over year. This cash flow statement covers 44 quarters of results from Sep 2015 through Jun 2026, standardized by Business Quant from the company’s SEC filings.

Cash Flow Statement Sep2015 Dec2015 Mar2016 Jun2016 Sep2016 Dec2016 Mar2017 Jun2017 Sep2017 Dec2017 Mar2018 Jun2018 Sep2018 Dec2018 Mar2019 Jun2019 Sep2019 Dec2019 Mar2020 Jun2020 Sep2020 Dec2020 Mar2021 Jun2021 Sep2021 Dec2021 Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Mar2026 Jun2026
Operating Activities
Net Income
-127.15M-141.25M-179.22M-185.83M-174.52M-110.53M-53.06M-77.74M-112.15M89.39M-116.59M-126.42M-85.97M-37.30M-136.00M-208.56M-106.44M-130.61M-122.93M-91.19M
Depreciation and Depletion
5.30M6.20M6.00M7.30M5.00M5.80M5.00M5.00M4.90M4.90M4.80M4.80M4.80M4.80M4.70M4.60M4.40M5.60M4.30M4.30M
Share-based Compensation
26.20M25.77M25.75M24.85M24.55M22.80M20.88M21.77M19.97M18.42M19.41M23.67M21.54M21.95M20.21M17.61M16.60M18.08M16.32M17.32M
Gains from Sales and Divestitures
Cash from Operations
-81.33M-86.04M-135.24M-141.96M-105.22M-113.33M8.80M-133.25M-39.86M-96.07M109.75M-95.58M-106.91M-50.03M-53.95M-113.88M-84.63M-92.55M-108.90M-83.50M
Depreciation, Depletion & Amortization
Depreciation & Amortization (CF)Depreciation & Amortization
5.32M6.26M6.04M7.27M5.02M5.85M5.05M4.96M4.92M4.90M4.83M4.84M4.74M4.84M4.74M4.65M4.43M5.66M4.32M4.28M
Change in Working Capital
Change in Receivables
0.00M0.15M-0.16M-0.08M-0.02M-0.05M70.00M-70.00M200.00M-200.00M25.00M-25.00M
Change in Accured Expenses
1.31M22.78M-1.62M9.92M27.96M-31.10M25.21M-11.58M-24.69M-9.19M9.44M9.28M-38.16M-7.85M43.00M-14.70M12.18M4.42M-13.02M-5.31M
Other Working Capital Changes
9.30M-4.86M-4.61M2.58M-5.03M5.46M-12.04M-3.91M-0.82M-6.45M-2.95M-2.35M0.19M14.73M-10.54M0.44M0.80M13.55M-0.43M4.38M
Investing Activities
Capital Expenditures
37.05M9.18M15.35M9.63M6.02M6.19M3.06M3.56M2.12M0.74M0.72M0.71M0.22M0.25M0.21M0.12M0.07M0.52M0.50M0.65M
Change in Intangibles
1.00M
Cash from Investing Activities
-565.18M-8.72M-114.52M-56.07M87.46M-175.53M117.83M216.92M121.35M-81.45M-97.80M-126.91M-161.60M105.83M-19.75M69.98M-119.23M37.20M-410.74M-55.66M
Financing Activities
Other financing activities
13.53M1.12M
Debt Issuance and Repayment
Long-Term Debt Issuances
600.00M
Change in Capital Stock
Net Equity Issued and Repurchased
10.65M10.35M14.14M2.48M5.40M16.77M1.56M9.00M280.75M-1.01M6.00M14.96M8.52M-0.02M278.11M111.49M6.16M8.30M
Misc.
Cash from Financing Activities
10.21M6.30M10.65M10.35M15.11M2.48M5.40M16.77M1.56M38.94M305.93M-0.47M9.64M16.88M10.59M2.26M296.77M116.41M591.91M7.18M
Exchange Rate Effect
-0.02M0.00M-0.03M-0.07M-0.10M0.12M0.03M0.03M-0.05M0.06M-0.01M0.00M0.07M-0.09M0.04M0.08M-0.03M0.00M-0.03M0.01M
Change in Cash
-636.32M-88.45M-239.13M-187.74M-2.74M-286.27M132.06M100.47M83.00M-138.53M317.88M-222.95M-258.80M72.59M-63.07M-41.56M92.88M61.06M72.24M-131.97M
Free Cash Flow
-118.38M-95.22M-150.59M-151.59M-111.23M-119.52M5.74M-136.80M-41.97M-96.81M109.03M-96.29M-107.13M-50.28M-54.15M-114.00M-84.71M-93.07M-109.40M-84.15M
Net Cash Flow
-636.30M-88.45M-239.10M-187.68M-2.64M-286.38M132.03M100.44M83.05M-138.59M317.89M-222.95M-258.88M72.67M-63.11M-41.65M92.91M61.06M72.27M-131.98M

CRISPR Therapeutics AG Cash Flow Statement API

Pull CRISPR Therapeutics AG's standardized financial statements into your own models, spreadsheets and apps with the Business Quant Financial Statements API. The request below follows the statement, frequency and period selected above. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/statements?ticker=CRSP&statement=CF&frequency=Quarter&period=all&api_key=YOUR_API_KEY